Model Developed for Predicting Disease Progression in Hep B Liver Cirrhosis

Model can predict acute-on-chronic liver failure in patients with hepatitis B liver cirrhosis-acute decompensation

Adobe Stock

THURSDAY, April 6, 2023 (HealthDay News) -- For patients with hepatitis B virus (HBV) liver cirrhosis-acute decompensation (LC-AD), a model combining computed tomography (CT) quantified extracellular liver volume (ECVIC-liver) and chronic liver failure consortium-acute decompensation score (CLIF-C ADs) can predict the occurrence of acute-on-chronic liver failure (ACLF), according to a study published online March 29 in Insights into Imaging.

Yang Xu, from Lanzhou University Second Hospital in China, and colleagues conducted a retrospective study to develop and validate a model for predicting the occurrence of ACLF within 90 days in patients with HBV LC-AD. Participants underwent dual-energy CT scans of the liver and were randomly assigned to a training group and a validation group (215 and 92 patients, respectively). The need for readmission within 90 days due to ACLF was the primary outcome.

The researchers found that CLIF-C ADs and ECVIC-liver were independent risk factors for ACLF. In the training and validation groups, the area under the receiver operating characteristic curves of the model combining CLIF-C ADs and ECVIC-liver were 0.893 and 0.838, respectively. Good agreement was seen between predicted and actual risks in calibration curves. The model had good clinical application in a decision curve analysis.

"The results of this study can be used to assist the clinic to better identify the early disease progression in LC-AD patients," the authors write.

Abstract/Full Text

Elana Gotkine

Elana Gotkine

Medically reviewed by Mark Arredondo, M.D.

Published on April 06, 2023

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ